US Patent 11318132 Diversion-resistant opioid formulations
Patent 11318132 was granted and assigned to Elysium Therapeutics, Inc. on May, 2022 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11318132 Diversion-resistant opioid formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.